(2S)-2-[[4-[(2-fluorophenyl)methoxy]phenyl]methylamino]propanamide
(2S)-2-[[4-[(2-fluorophenyl)methoxy]phenyl]methylamino]propanamide Basic information
- Product Name:
- (2S)-2-[[4-[(2-fluorophenyl)methoxy]phenyl]methylamino]propanamide
- Synonyms:
-
- (2S)-2-[[4-[(2-fluorophenyl)methoxy]phenyl]methylamino]propanamide
- ralfinamide
- (S)-2-[[4-[(2-Fluorobenzyl)oxy]benzyl]amino]propanamide
- (2S)-2-(4-(2-Fluorobenzyloxy)benzylamino)propanamide
- Safinamide impurity 3/(S)-2-((4-((2-fluorobenzyl)oxy)benzyl)amino)propanamide
- (2S)-2-[[4-[(2-fluorophenyl)methoxy]phenyl]methylamino]propanamide/Safinamide Impurity
- Safinamide-6
- Guadecitabine Sodium
- CAS:
- 133865-88-0
- MF:
- C17H19FN2O2
- MW:
- 302.34
- EINECS:
- 200-582-5
- Product Categories:
-
- Inhibitor
- Mol File:
- 133865-88-0.mol
(2S)-2-[[4-[(2-fluorophenyl)methoxy]phenyl]methylamino]propanamide Chemical Properties
- Boiling point:
- 479.0±40.0 °C(Predicted)
- Density
- 1.189
- storage temp.
- 2-8°C(protect from light)
- solubility
- DMSO: ≥ 125 mg/mL (413.44 mM)
- pka
- 16.03±0.50(Predicted)
- form
- Solid
- color
- White to off-white
(2S)-2-[[4-[(2-fluorophenyl)methoxy]phenyl]methylamino]propanamide Usage And Synthesis
Uses
Ralfinamide (FCE-26742A) is an orally available Na+ blocker derived from α-aminoamide, with function of suppressing pain[1][2].
Biological Activity
Ralfinamide (FCE-26742A) is an orally available sodium channel blocker derived from α-aminoamide with analgesic properties.
in vivo
Ralfinamide (30 mg/kg, 60 mg/kg; p.o.; twice daily; 42 days) treated with Ralfinamide (80 mg/kg; p.o.; twice daily; 7 days) preoperatively suppresses neuropathic pain[1].
| Animal Model: | 81 adult male Sprague–Dawley male rats (260–460 g)[1] |
| Dosage: | 80 mg/kg (7 days preoperatively), 30 mg/kg, 60 mg/kg (postoperative) |
| Administration: | Oral gavage; twice daily; until postoperative day 42 |
| Result: | Suppressed neuropathic pain. |
References
[1] Zhang SH, et al. Ralfinamide administered orally before hindpaw neurectomy or postoperatively provided long-lasting suppression of spontaneous neuropathic pain-related behavior in the rat. Pain. 2008 Oct 15;139(2):293-305. DOI:10.1016/j.pain.2008.04.020
[2] Liang X, et al. Effects of ralfinamide in models of nerve injury and chemotherapy-induced neuropathic pain. Eur J Pharmacol. 2018 Mar 15;823:27-34. DOI:10.1016/j.ejphar.2018.01.041
(2S)-2-[[4-[(2-fluorophenyl)methoxy]phenyl]methylamino]propanamideSupplier
- Tel
- 400-6009262 16621234537
- chenyj@titansci.com
- Tel
- 0510-85629785 18013409632
- sales@reading-chemicals.com
- Tel
- sales@ahpharmatech.com
- Tel
- 13621943973
- sales@shjiyipharmatech.com
- Tel
- 86(21)68097365
- sales@anpharma.net
(2S)-2-[[4-[(2-fluorophenyl)methoxy]phenyl]methylamino]propanamide(133865-88-0)Related Product Information
- Safinamide Impurity 11
- Safinamide Impurity 8
- Safinamide Impurity 1
- Safinamide
- (S)-2-((3-((3-fluorobenzyl)oxy)benzyl)amino)propanamide
- 3-(3-fluorobenzyl)-4-(3-fluoro-benzyloxy)benzaldehyde
- FCE 28073
- Safinamide Impurity 9
- Safinamide Impurity 5
- (S)-2-((4-((4-fluorobenzyl)oxy)benzyl)amino)propanamide
- (S)-2-((4-(benzyloxy)benzyl)amino)propanamide
- Safinamide Impurity 7
- Safinamide Impurity 3
- Safinamide Impurity 4
- Safinamide Impurity 2
- Safinamide Impurity 6
- Safinamide Impurity 5
- Propionamide